Valuation
- Market cap
- 205,000
- Revenue TTM
- $0
- Net income TTM
- $-7,350,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 5,896,400
- Avg volume
- 426,953
- Day's range
- $0.50 – $1.54
- Shares out
- 410,000
- Stochastic %K
- 0%
- Beta
- 0.01
- Analysts
- Strong Buy
- Price target
- $48.00
Company profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as w...
Show more
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 44 14 1433 7557
- Website
- https://tcbiopharm.com
- Address
- Maxim 1, 2 Parklands Way Holytown, Motherwell, United Kingdom
Latest news
No headlines yet.
